Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Friday, July 4, 2025 in observance of the Fourth of July holiday.  Have a healthy, happy holiday.

Hide
Quest Diagnostics

Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens

ACMT 2024

American College of Medical Toxicology

Washington, DC, April 10-14, 2024

Poster presentation: Prevalence of Novel Psychoactive Substances in Routine Prescription Drug Monitoring Clinical Urine Specimens

Authors: Neifeld JR, Solano RI, Smith MP, Bartock SH

Specialty: Toxicology, Prescription Drug Monitoring

Related content

Test FAQ
Novel Psychoactive Substances (NPS) Panel
Conference Presentation
What’s Next on the Drug Abuse Landscape: Development of Laboratory Testing for Novel Psychoactive Substances (NPS)
Audio Podcast
Medication Adherence Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.